In thyroid cancer, increased NIBAN1 expression has been described in different tumors subtypes: microcarcinomas; papillary carcinomas; follicular carcinomas; metastases, and tumors with oxyphilic cytoplasm, such as Hürthle cell carcinoma, and some oxyphilic cells, originating from Hashimoto’s Thyroiditis (Cerutti et al., 2004; Maciel et al., 2005; Cerutti et al., 2006; Matsumoto et al., 2006; Cerutti, 2011; Patel et al., 2011; Carvalheira et al., 2013; Carvalheira et al., 2015; Nozima et al., 2019). Here, NIBAN1 is linked to thyroid gland carcinoma.